

CEREVEL THERAPEUTICS HOLDINGS, INC.

222 Jacobs Street, Suite 200
Cambridge MA 02141

VIA EDGAR

November 16, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549

Re: Cerevel Therapeutics Holdings, Inc.
Acceleration Request for Registration Statement on Form S-3
Filed November 8, 2022
File No. 333-268235

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cerevel Therapeutics Holdings, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to November 18, 2022, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable.

If you have any questions regarding this request, please contact Nicole Daley of Goodwin Procter LLP at (617) 570-1354.

Sincerely,

CEREVEL THERAPEUTICS HOLDINGS, INC.

/s/ Mark Bodenrader

Mark Bodenrader

Interim Chief Financial Officer

cc: N. Anthony Coles, *Cerevel Therapeutics Holdings, Inc.*
Scott M. Akamine, *Cerevel Therapeutics Holdings, Inc.*
John Mei, *Cerevel Therapeutics Holdings, Inc.*
Stuart M. Cable, *Goodwin Procter LLP*
Nicole Daley, *Goodwin Procter LLP*